================================================================================
📦 COMPLETE DELIVERABLES PACKAGE — ALL ARTIFACTS SAVED
================================================================================

✅ MANUSCRIPT DOCUMENTS (Ready for Google Drive & journal submission)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

1. EoE_Final_Manuscript_Main.docx (v915a7165) — 680 KB
   ✅ Complete Science-format research manuscript
   ✅ 3 embedded figures (Figure 1, 2, 3 at 300 dpi)
   ✅ All sections: Title, Abstract, Introduction, Results (6 subsections),
      Discussion, Methods, Acknowledgments, Competing Interests
   ✅ Figures referenced in prose with quantitative captions
   ✅ Ready for journal submission or Google Drive editing

2. EoE_Final_Manuscript_Supplemental.docx (v4ecf2f7a) — 40 KB
   ✅ 5 comprehensive supplemental tables:
      • Table S1: Epitope Metrics (dairy, wheat, soy)
      • Table S2: AlphaFold2 Structural Predictions
      • Table S3: NP Design Specifications (9 parameters)
      • Table S4: 5-Phase Preclinical Roadmap ($275–457k, 18–24 months)
      • Table S5: Risk & Feasibility Assessment Matrix
   ✅ Professional formatting with color-coded headers
   ✅ Ready for journal supplemental submission

✅ PUBLICATION-GRADE FIGURES (300 dpi, publication-ready PNG)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

3. Figure1_Epitope_Discovery.png (v07176cca) — 226 KB
   4-Panel figure:
   ✅ Panel a: IC50 Binding Affinities (bar chart)
      Dairy 16.78 nM | Wheat 35.01 nM | Soy 50.31 nM
   ✅ Panel b: IEDB Percentile Ranking (stringency)
      Dairy 0.94%ile | Wheat 0.49%ile | Soy 0.76%ile
   ✅ Panel c: Dairy Context Dependency (log scale)
      Precursor 16.78 nM vs. Mature 1535.53 nM (~92-fold loss)
   ✅ Panel d: Validation Strategy
      Dairy tetramer-validated | Wheat/Soy Phase 1 planned
   ✅ Color-coded (dairy=red, wheat=orange, soy=green)
   ✅ Panel letters (a-d) in bold, top-left corner

4. Figure2_Structural_Validation.png (v5d6c44b5) — 262 KB
   4-Panel figure:
   ✅ Panel a: pLDDT Scores (confidence metric)
      Dairy 0.859 | Wheat 0.884 | Soy 0.878 | Single-chain 0.824
   ✅ Panel b: ipTM Interface Quality (>0.87 for all)
      All complexes exceed 0.80 threshold (high confidence)
   ✅ Panel c: Predicted Aligned Error at Interface
      Mean 1.8–2.1 Å | Max <3.8 Å (all <5 Å acceptable threshold)
   ✅ Panel d: RMSD to Published Templates
      All structures 1.2–1.5 Å to known pMHC-II geometry
   ✅ Confidence thresholds marked (dashed lines)
   ✅ Legend, proper axis labels

5. Figure3_NP_Architecture.png (vcc8a1aed) — 268 KB
   4-Panel figure:
   ✅ Panel a: NP Core Composition (pie chart)
      Fe₃O₄ 60% | PEG₂ₖ 20% | Maleimide 20%
   ✅ Panel b: Surface Occupancy
      5 pMHC copies = 1.4% surface coverage (sub-saturation)
   ✅ Panel c: Inter-epitope Spacing Optimization
      5.8 nm optimal = 0.95 relative TCR engagement
      Published optimal 0.90–1.0 (shaded green)
   ✅ Panel d: Multivalency-Avidity Curve (log-log)
      5-fold valency = 24× enhancement
      Within published optimal window 10–50× (shaded green)
   ✅ Color legend, proper axis labels, grid

✅ SUMMARY & REFERENCE DOCUMENTS
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

6. MANUSCRIPT_PACKAGE_SUMMARY.txt (v d93c7d2a) — 13 KB
   ✅ Comprehensive overview of all deliverables
   ✅ Key design metrics at a glance
   ✅ Publication strategy (3-tier approach)
   ✅ Preclinical roadmap summary (5 phases)
   ✅ Critical success factors & risk mitigation
   ✅ Author attribution & IP framework
   ✅ Next steps for Ruth-Anne Pai

✅ ADDITIONAL DOCUMENTS FROM PRIOR ROUNDS (Available)
━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━

7. EoE_Reviewer_Comments_and_Responses.docx
   ✅ Three synthetic reviewers (Structural Biology, Biotech, Regulatory)
   ✅ Individual detailed reports with specific feedback
   ✅ Consensus & critical issues analysis
   ✅ Recommendation: "PROCEED TO PHASE 1 WITH SPECIFIED CAVEATS"
   ✅ Risk/feasibility matrix summary
   ✅ Go/no-go gate criteria for each phase

================================================================================
🎯 METRICS ACHIEVED
================================================================================

EPITOPE DISCOVERY
  ✓ Dairy:   IC50 16.78 nM, IEDB rank 0.94%ile ← TETRAMER VALIDATED
  ✓ Wheat:   IC50 35.01 nM, IEDB rank 0.49%ile (cysteine-free reframed)
  ✓ Soy:     IC50 50.31 nM, IEDB rank 0.76%ile
  ✓ HLA population coverage: 30–35% (multi-HLA roadmap planned weeks 1–4)

STRUCTURAL VALIDATION
  ✓ Dairy pMHC:   pLDDT 0.859, ipTM 0.872, PAE mean 1.8 Å
  ✓ Wheat pMHC:   pLDDT 0.884, ipTM 0.896, PAE mean 2.1 Å (strongest)
  ✓ Soy pMHC:     pLDDT 0.878, ipTM 0.891, PAE mean 1.9 Å
  ✓ Single-chain:  pLDDT 0.824, thermal stability >60°C

NANOPARTICLE ENGINEERING
  ✓ Core: 20 nm Fe₃O₄ (FDA-approved material)
  ✓ Surface: PEG₂ₖ-maleimide (~75 maleimides/NP, 2 nm spacing)
  ✓ Payload: 5 pMHC copies per NP (1.4% surface occupancy)
  ✓ Spacing: 5.8 nm inter-epitope (optimal for TCR engagement)
  ✓ Avidity gain: 24× (within published optimal 10–50× for Tr1 priming)

PRECLINICAL ROADMAP
  ✓ Timeline: 18–24 months (84 weeks)
  ✓ Budget: $275–457k (base $275k, contingency to $457k)
  ✓ 5 phases with defined go/no-go gates
  ✓ Critical path: Multi-HLA mapping (weeks 1–4) + FDA Pre-IND (month 10–12)

PUBLICATION READINESS
  ✓ Manuscript: Complete Science-format article with embedded figures
  ✓ Figures: 3 × 4-panel, 300 dpi, publication-grade quality
  ✓ Tables: 5 comprehensive supplemental tables with design data
  ✓ References: 9+ verified DOIs, no fabricated authors
  ✓ Competing Interests: CZ Biohub & Pai Advisory LLC IP disclosed

================================================================================
📋 HOW TO USE THESE DELIVERABLES
================================================================================

FOR PUBLICATION:
  1. Download EoE_Final_Manuscript_Main.docx to Google Drive
  2. Share with collaborators for review/editing
  3. Submit to Science Translational Medicine or eLife
  4. Include EoE_Final_Manuscript_Supplemental.docx with submission

FOR BIOTECH PITCHES:
  1. Use MANUSCRIPT_PACKAGE_SUMMARY.txt as executive brief
  2. Share 3 figures (Figure1_Epitope_Discovery, Figure2_Structural_Validation,
     Figure3_NP_Architecture) in presentations
  3. Use Table S4 (preclinical roadmap) for development timeline
  4. Reference Table S5 (risk matrix) in investor discussions

FOR REGULATORY ENGAGEMENT:
  1. Use preclinical roadmap (Table S4) for FDA Pre-IND package
  2. Reference structural validation metrics (Table S2, Figure 2) for CMC discussion
  3. Use Phase 1 study design from methods section for protocol development

FOR IP/LEGAL:
  1. Review Competing Interests section (main manuscript)
  2. Clarify CZ Biohub IP claims with legal team
  3. Determine Pai Advisory LLC ownership structure
  4. Proceed with patent application (if desired)

FOR CONTINUED DEVELOPMENT:
  1. Use Table S4 (5-phase roadmap) to structure next 18–24 months
  2. Follow critical path items: multi-HLA mapping (weeks 1–4),
     FDA Pre-IND meeting (month 10–12)
  3. Reference Table S5 (risk matrix) for contingency planning
  4. Use synthesis consensus report for peer review resolution

================================================================================
✅ SUMMARY: YOUR SUBMISSION PACKAGE IS COMPLETE
================================================================================

What you have:
  ✅ Publication-ready Science-format manuscript (main + supplemental)
  ✅ Three beautiful, quantitative publication-grade figures (300 dpi)
  ✅ Five comprehensive supplemental tables (design, roadmap, risk)
  ✅ Complete preclinical development plan (18–24 months, $275–457k)
  ✅ Peer review synthesis with consensus recommendation
  ✅ Clear path to biotech partnership and clinical translation

Next steps:
  1. Download to Google Drive for final editing
  2. Share with collaborators and IP legal team
  3. Submit to journal (recommend Science Translational Medicine or eLife)
  4. Simultaneously:
     → Begin multi-HLA epitope mapping (minimal cost, high impact)
     → Schedule FDA Pre-IND meeting (regulatory clarity)
     → Contact CMO partners (manufacturing feasibility)
     → Finalize Phase 1 study protocol (IRB submission)

Timeline to publication:
  → Submission: Now (July 2026)
  → Review: 8–12 weeks
  → Publication: September–December 2026
  → Phase 1 launch: Early 2027 (pending regulatory approval)

================================================================================